

# UC San Diego

## UC San Diego Previously Published Works

### Title

Tobacco Quitline Callers Who Use Cannabis and Their Likelihood of Quitting Cigarette Smoking

### Permalink

<https://escholarship.org/uc/item/05g9v7rt>

### Authors

Zhu, Shu-Hong

Tedeschi, Gary J

Li, Shuwen

et al.

### Publication Date

2024-03-01

### DOI

10.1016/j.amepre.2024.03.007

Peer reviewed

1 **Tobacco Quitline Callers Who Use Cannabis and Their Likelihood of Quitting Cigarette Smoking**

2  
3  
4 Shu-Hong Zhu, Ph. D.<sup>1,2</sup>  
5 Gary J. Tedeschi, Ph.D.<sup>1</sup>  
6 Shuwen Li, MPP.<sup>1</sup>  
7 Jijiang Wang, M.Med.<sup>1</sup>  
8 Emily Aughinbaugh, B.A.<sup>1</sup>  
9 Andrea S. Pratt, Ph.D.<sup>1</sup>  
10 Yue-Lin Zhuang, Ph.D.<sup>1</sup>

11  
12  
13  
14  
15  
16  
17  
18 **Address correspondence to:** Shu-Hong Zhu, PhD, The Herbert Wertheim School of Public Health and  
19 Human Longevity Science, University of California, San Diego, 9500 Gilman Drive #0905, La Jolla, CA,  
20 92093-0905, [szhu@ucsd.edu], 858-300-1056.

21  
22 **Word count:** 3,041

23 **Pages:** 14

24 **Tables:** 3

25  
26  
27  

---

1 <sup>1</sup> Moores Cancer Center, University of California, San Diego

2 <sup>2</sup> Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.

28 **ABSTRACT**

29

30 **Introduction:** Cigarette smoking continues to decline in the U.S., but cannabis use is increasing.  
31 Many people who smoke cigarettes also use cannabis. This study examines characteristics of  
32 persons who co-use and those who do not co-use, and the likelihood of quitting cigarettes for  
33 callers to Kick It California (KIC), a large state tobacco quitline.

34

35 **Methods:** Data were examined from KIC callers from January 2020 through December 2023  
36 (N=45,151) including those from a sub-group randomly sampled and reached for evaluation at 7  
37 months after quitline enrollment (N=3,545). The rate of cigarette smoking cessation at 7 months  
38 post-enrollment for people who co-use cannabis compared with that for people who do not.  
39 Analyses started in 2023 and concluded in January 2024.

40

41 **Results:** More than a quarter (27.2%) of KIC callers co-used cannabis. They were more likely to  
42 be male, younger, and have a mental health condition than those who did not. Those who co-use  
43 cannabis and those who do not have similar rates of receiving quitline counseling or using FDA-  
44 approved cessation aids. Controlled for effects of personal characteristics and use of smoking  
45 cessation services, people who co-use cannabis were less likely to quit cigarette smoking than  
46 those who do not at 7 months post-enrollment, 23.2% versus 28.9% ( $p<0.001$ ). Among those  
47 who co-use, 42.9%, intended to quit using cannabis in the next 30 days.

48

49 **Conclusions:** A substantial percentage of tobacco quitline callers use cannabis. Those who do  
50 co-use quit cigarette smoking at a lower rate than those who do not. Over forty percent of people  
51 who co-use reported intention to quit cannabis, making tobacco quitlines a rich environment to  
52 learn about people who co-use and develop strategies for intervention.

53

54

55 **INTRODUCTION**

56

57 Rates of cigarette smoking for adults in the U.S. have decreased significantly in recent years,  
58 reaching an all-time low of 11.5% in 2021, down from 15.1% in 2015.<sup>1,2</sup> However, cannabis use  
59 continues to rise. For instance, the National Survey on Drug Use and Health (NSDUH) showed  
60 that the percentage of U.S. adults reporting past-month cannabis use reached 13.7% in 2021, up  
61 from 8.4% in 2015.<sup>3,4</sup>

62

63 Co-use of tobacco and cannabis is common.<sup>5-9</sup> While co-use broadly refers to both tobacco and  
64 cannabis consumption, it also refers to concurrent administration like the use of blunts  
65 (hollowed-out cigars filled with marijuana) or successive administration called “chasing,” using  
66 one product right after the other.<sup>10-12</sup> Tobacco and cannabis are often entwined. Tobacco use is  
67 more prevalent among people who use cannabis. For example, according to the 2015 NSDUH,  
68 people who use cannabis daily and non-daily reported tobacco use at rates of 54.6% and 40.2%,  
69 respectively, compared to 15.1% for people who did not use cannabis at all.<sup>13</sup> Also, cannabis use  
70 is more common among people who use tobacco than among those who do not use tobacco.<sup>9,14,15</sup>  
71 In California for example, the 2022 California Health Interview Survey<sup>16</sup> showed that adults who  
72 had smoked cigarettes in the past month were more than twice as likely to report past-month  
73 cannabis use as adults who did not smoke cigarettes (37.6% vs. 16.0%, respectively).<sup>17</sup>

74

75 It is well established that cigarette smoking is the leading cause of preventable disease, disability,  
76 and death in the U.S.<sup>18,19</sup> The health risks of cannabis use, however, are not as well-documented

77 and clear as those of tobacco use.<sup>20,21</sup> The lack of a simple public health message on cannabis is  
78 in part attributable to the medicinal use of cannabis.<sup>22</sup> However, mixing tobacco and cannabis  
79 smoking is likely to lead to worse health outcomes than using either alone.<sup>23–26</sup> The present study  
80 focused on assessing the prevalence of co-use in a tobacco quitline setting and intended to  
81 examine if co-use of cannabis affects cigarette smoking cessation rates.

82

83 Studies on the effects of cannabis use on tobacco cessation have reported conflicting results.<sup>27–29</sup>  
84 Some have found that cannabis use impedes tobacco cessation efforts,<sup>9,14,30–34</sup> while others have  
85 not.<sup>35–37</sup> Some of these studies were based on clinical samples while others were on population  
86 surveys. For the studies that are based on clinical samples, the question of whether cannabis use  
87 impedes tobacco cessation is often motivated by another related question, which is whether  
88 tobacco cessation programs should encourage people who co-use to quit both substances or focus  
89 on tobacco alone.

90

91 This study is based on a large sample of people who smoke who called a state tobacco quitline.  
92 State quitlines in the U.S. offer evidenced-based tobacco cessation services<sup>38</sup> and receive calls  
93 from clients who use a variety of tobacco products, many of whom have co-morbid substance  
94 use or mental health conditions.<sup>39,40</sup> Specifically, there is a sizable number of people who co-use  
95 cannabis calling tobacco quitlines.<sup>31,35,41</sup> One study from New York, a state where recreational  
96 cannabis was illegal at the time, reported 8.3% of the quitline callers used cannabis.<sup>31</sup> Another  
97 study of three quitlines in states that had legalized recreational use of cannabis found that 1 in 4  
98 callers used cannabis.<sup>41</sup> As legalization of cannabis for recreational use increases in the U.S.,<sup>42</sup> it  
99 may be easier for clients to talk about cannabis use when engaging with tobacco quitlines. State

100 quitlines across the U.S. collectively serve a very large number of people who use tobacco and  
101 are in a good position to study cannabis co-use and aid in the understanding of cessation  
102 considerations for those who co-use.

103

104 The present study examined four years of data (2020–2023) from California’s tobacco quitline.  
105 Recreational use of cannabis was legalized in California in 2018. On the heels of this legislation,  
106 the state tobacco quitline added a question about cannabis use to its standard tobacco cessation  
107 intake for all callers. This allowed for an examination of the trend of cannabis use in a tobacco  
108 quitline setting, as well as characteristics of those who use cannabis and tobacco cessation  
109 services received by those who co-use cannabis and tobacco and those who do not. A key issue  
110 in the analysis was whether people who co-use had a different cigarette-cessation rate than those  
111 who do not.

112

## 113 **METHODS**

114

### 115 **Study Population**

116 This study uses data from Kick It California (KIC), formerly the California Smokers’ Helpline.  
117 Since 1992, KIC has provided services at no cost to California residents who use tobacco,  
118 including those who smoke cigarettes, vape nicotine and chew tobacco, as well as their family  
119 and friends (a.k.a., proxy clients), and offers support to health professionals.<sup>43</sup> The services are  
120 based on the results of multiple trials that demonstrated the efficacy of its telephone counseling  
121 protocol for smoking cessation.<sup>44,45</sup>

122

123 All participants in the current study initiated calls to KIC and completed the standard telephone  
124 intake session, which assessed individual needs and determined a course of action (e.g.,  
125 telephone counseling/coaching, self-help materials, referral to other programs). All participants  
126 provided oral consent for participation. The study, including consent procedures, was approved  
127 by the Human Research Protections Program of the University of California, San Diego  
128 (#171562). This study includes callers who enrolled in KIC services from January 2020 to  
129 December 2023. A total of 45,231 callers were assessed about their present marijuana use; those  
130 who responded with "don't know" (n=27) and those who declined to answer (n=53) were  
131 excluded from the analysis. Therefore, the effective sample size for this study was 45,151.

132

### 133 **Measures**

134 The intake session at KIC starts with a review of confidentiality and consent followed by a series  
135 of questions, including basic demographics, type of tobacco or vape used, self-reported physical  
136 and mental health conditions, interest in telephone counseling, and interest in cessation  
137 pharmacotherapy.

138

139 In December 2019, a question about cannabis use was added to the intake reading, "Do you use  
140 marijuana?" In March 2023, this question was refined to enhance precision and now reads,  
141 "Have you used marijuana in any form in the last 30 days?" Clients could answer "Yes," "No,"  
142 "Don't know," or could refuse to answer. In July 2023, a follow-up question was added asking  
143 those who used cannabis about their intention to quit, "Do you plan to quit using marijuana in the  
144 next 30 days?" with callers answering "Yes," "No," "Don't Know." On rare occasions, clients

145 were not asked the cannabis use question (45 out of 45,276 clients). This happened when clients  
146 struggled to process and answer questions, if clients were overly challenging or combative, or if  
147 calls became disconnected before reaching the question.

148

149 For clients who reported co-use and went on to counseling, coaches offered information on  
150 topics such as health risks of cannabis, co-use of cannabis and tobacco, the potential for one  
151 substance to trigger cravings for the other, and intentions to quit cannabis. For callers who  
152 wanted to quit cannabis, referrals were provided to substance use treatment programs.

153

154 For the four-year study period, a random sample of participants who answered the cannabis use  
155 question was selected to be followed up at 7 months post-enrollment. A total of 8,619  
156 participants were sampled during this period, and 3,545 were reached, for a response rate of  
157 41.1%. The response rate was lower for those who used cannabis than for those who did not use  
158 cannabis at baseline (38.9% and 42.0% respectively). For those reached from this subsample,  
159 evaluators (independent of counselors) assessed callers' current cigarette use, attempts to quit  
160 cigarette smoking, use of counseling services and smoking cessation pharmacotherapy, and  
161 satisfaction with the program.

162

### 163 **Statistical Analysis**

164 Descriptive analysis examined the characteristics of callers who co-use cannabis and tobacco and  
165 callers who do not, along with 95% confidence intervals for comparison purposes. These  
166 descriptive analyses were planned for everyone who answered the question about cannabis use at  
167 baseline. The analysis of smoking cessation focused only on those who were randomly sampled



168 for follow-up and were reached by evaluators. A multiple regression analysis was conducted to  
169 compare the difference in smoking cessation rate between cigarette-only callers and those who  
170 co-use, controlling for the effects of baseline covariates such as gender, age, and ethnicity and  
171 participants' use of counseling and pharmacotherapy. Finally, the intent to quit cannabis was  
172 examined only for those who called the quitline after July 2023 when the question was added to  
173 intake. Analyses were conducted in 2023-2024 using SAS 9.4 software.<sup>46</sup>

174

## 175 **RESULTS**

176

177 Over the four-year period, 27.2% of KIC callers reported cannabis use, with percentages in each  
178 year as follows: 25.9% in 2020, 28.0% in 2021, 27.6% in 2022, and 27.6% in 2023 (data not  
179 shown in tables). In March 2023, the cannabis use measurement was refined from the original  
180 “Do you use marijuana?” to, “Have you used marijuana in any form in the last 30 days?” When  
181 compared over the same length of time, ten months before and after the wording change, there  
182 was no significant difference in the percentage of those reporting cannabis use(27.3% from May  
183 2022 to February 2023 vs. 27.7% from March to December 2023;  $p=0.53$ ).

184

185 Table 1 compares those who reported cannabis use with those who did not. Clients who used  
186 cannabis were more likely to identify as male, another gender or choose not to disclose their  
187 gender identity than to identify as female. Clients who used cannabis were more likely to be  
188 younger; more likely to have some college education (but without the 4-year degree); more likely  
189 to be White, Black or American Indian/Alaska Native, and more likely to have multi-racial

190 ethnic background, but less likely to be Hispanic or Asian American/Pacific Islander. Table 1  
191 also shows that people who used cannabis were more likely to report having a mental health  
192 condition. Clients who used cannabis and those who did not were similar in the number of  
193 cigarettes they smoked, but those who used cannabis were more likely to vape nicotine.

194

195 Table 2 compares the likelihood of these two groups receiving telephone counseling from KIC or  
196 using any FDA-approved pharmacotherapy during the 7 months following their enrollment at  
197 KIC. These data were obtained from those who were randomly sampled and completed the  
198 evaluation at 7 months post-enrollment. Clients who used cannabis and those who do not have  
199 similar rates of completing at least one counseling call with KIC counselors (72.0% vs 74.5%,  
200  $p=0.12$ ) and similar rates of using any FDA-approved pharmacotherapy for tobacco cessation  
201 (64.1% vs. 64.9%,  $p=0.68$ ).

202

203 Table 3 shows the 30-day quit rate at 7 months. Clients who used cannabis were less likely to  
204 succeed in quitting smoking than those who did not use cannabis, 23.2% versus 28.9%  
205 ( $p<0.001$ ). A multiple logistic regression controlling for the effects of baseline characteristics and  
206 the use of counseling, pharmacotherapy and nicotine vaping confirmed that the difference in quit  
207 rate remained statistically significant ( $p<0.001$ ).

208

209 The multiple logistic regression analysis also revealed that gender identity did not predict  
210 cigarette cessation outcome. Younger clients (those under 25 or between 25 and 44, compared to  
211 those aged 65 and older) were more likely to quit cigarette smoking. Regarding race/ethnicity,  
212 Black participants had lower odds of successful cessation compared to White participants. No

213 other racial/ethnic group had a lower probability of quitting than White participants. Clients with  
214 mental health conditions also had lower odds of quitting cigarettes. Clients who smoked 15 or  
215 more cigarettes per day at baseline were less likely to quit smoking than those who smoked  
216 fewer. In contrast, those who reported vaping nicotine at baseline were more likely to quit  
217 smoking than those who did not vape. Those who received counseling were more likely to quit  
218 than those who did not receive counseling, and those who used any FDA-approved quitting aid  
219 had higher odds of quitting compared to those who did not.

220

221 Since March 2023, KIC callers who reported cannabis use were asked if they planned to quit  
222 using marijuana in the next 30 days (N=697). Among these callers, 42.9% responded with “Yes.”  
223 Intention to quit for females was lower than for males, but not significantly (40.6%, vs. 45.9%,  
224  $p=0.16$ ). Callers who identified as “other gender” (or declined to state their gender identity) also  
225 had a lower rate (33.3%) than males, but the difference was not statistically significant.

226

227

## 228 **DISCUSSION**

229

230 This study with over 45,000 people who smoke cigarettes calling the California state quitline  
231 found that more than a quarter of them (27.2%) used cannabis. This percentage is similar to that  
232 reported from several other state quitlines where recreational cannabis use is also legal.<sup>41</sup>

233 Compared to cannabis use prevalence among Californians who smoke cigarettes at large,

234 however, this is substantially lower. About 37% of those who smoke cigarettes in California use

235 cannabis.<sup>17</sup> This was somewhat expected given that the state quitline, KIC, is advertised as a  
236 tobacco cessation program, not a cannabis cessation program. Still, the fact that a large number  
237 of people who co-use tobacco and cannabis call the state tobacco quitline each year affords an  
238 opportunity to understand this group and to develop strategies to help them.<sup>47</sup>

239

240 The quitline caller profile for people who co-use tobacco and cannabis largely reflects the  
241 population profile of people who co-use.<sup>8,48,49</sup> Quitline callers who co-used tended to be younger,  
242 had some college experience, were more likely to vape nicotine, and were more likely to report  
243 mental health conditions. These findings are consistent with those reported in survey studies  
244 investigating co-use of cannabis and tobacco in the general population.<sup>8,48,49</sup>

245

246 The people who co-use in this study were also found to have a lower rate for quitting cigarettes.  
247 Longitudinal studies with population-representative samples of U.S. adults have found that co-  
248 use of cannabis at baseline was associated with reduced odds of stopping cigarette smoking at  
249 follow-up,<sup>34,50</sup> although one population study reported that people who co-used were no less  
250 likely to quit cigarettes than those who do not.<sup>37</sup> Among the studies with individuals who seek  
251 help to quit cigarette smoking, including those with quitline callers, most have found that people  
252 who co-use tend to be less likely to succeed in quitting cigarette smoking than those who do not  
253 co-use.<sup>9,31–33,35</sup>

254

255 The present study found that in addition to co-use being a predictor of a lower rate in quitting  
256 cigarettes, several demographic and behavioral variables also predicted quitting. Black  
257 participants had a lower rate than White participants, and older participants had a lower rate than

258 younger participants. Higher cigarette consumption level and having self-reported mental health  
259 conditions predicted lower quit rates. A multiple regression model controlling for the effects of  
260 these baseline variables, however, showed that cannabis use was still associated with lower odds  
261 of quitting cigarettes.

262

263 The reason people who co-use had a harder time quitting cigarettes in this study is not obvious. It  
264 might have been that cannabis intoxication or the method of administration enhanced the positive  
265 effects of nicotine.<sup>23,51-54</sup> It is also possible that since both cannabis and tobacco have shared use  
266 pathways, cannabis use may serve as a behavioral cue or trigger for nicotine use.<sup>23,55-58</sup> People  
267 who co-use are also more likely to have mental health conditions, which makes it harder to quit  
268 any substance.<sup>23,51-54,58</sup> Additionally, smoking cessation often requires a shift in self-image from  
269 smoker to nonsmoker.<sup>59,60</sup> It is difficult to view oneself as a nonsmoker while continuing to  
270 smoke other substances such as cannabis. All these possible reasons are worthy of examination  
271 in future studies.

272

273 If cannabis use and smoking are in fact intertwined and trigger one another, then it begs the  
274 question as to whether programs should encourage people who co-use to quit both substances at  
275 once. Research on co-use of tobacco and other substances have indicated that giving up both  
276 substances at once may be a good approach and that quitting tobacco can enhance recovery from  
277 other substances.<sup>61-63</sup> However, quitting both substances at once can be overwhelming. This  
278 requires clinicians to discuss the pros and cons of a “one-at-a-time” versus an “all-at-once”  
279 approach with those interested in quitting both substances. Whether it is better to encourage

280 concurrent quitting of cannabis and tobacco or to tackle one substance at a time is another  
281 compelling direction for additional research.

282

### 283 **Limitations**

284 This study has a few limitations. The study found an association between cannabis use and the  
285 probability of quitting cigarette smoking. The underlying causal link is not identified. Also, at  
286 intake, cannabis use was not assessed in detail, such as modality, quantity, frequency of use, and  
287 history of cannabis cessation. As a tobacco cessation quitline, these topics could be seen as  
288 outside of scope, but they certainly have clinical relevance given that the use of cannabis was  
289 linked with a significantly lower tobacco cessation rate. Finally, most of the evaluation calls in  
290 this study were attempted in the throes of the COVID-19 pandemic, which might have  
291 contributed to a low response rate in follow-up evaluation. Of note, the group using both  
292 substances had a lower response rate. An analysis that assumed those lost to follow-up as  
293 “continued to smoke cigarettes” would have made the group difference in quit rate even larger  
294 than what was currently reported. Thus, it was decided not to make this assumption in the  
295 analysis, rendering the result more conservative.

296

297 Limitations notwithstanding, this study reports two statistics that merit the attention of public  
298 health programs, especially those that serve a large number of people who smoke cigarettes such  
299 as state quitlines. Cannabis use is associated with a lower probability of cigarette cessation and  
300 42.9% of those using cannabis who were queried of their intention (N=697) expressed intent to  
301 quit using cannabis in the next 30 days. Another quitline study found a similar percentage of  
302 people who smoke wanting to quit cannabis.<sup>41</sup> These findings suggest that state tobacco quitlines

303 across the U.S. may need to consider creating special protocols to help these people who co-use  
304 improve their tobacco cessation rate or to help them stop using cannabis, rather than only  
305 referring clients to substance use treatment programs for cannabis cessation. In other words, it  
306 would be more efficient if quitlines could help them when they are already on the line, and  
307 interested in making a cannabis cessation plan. Given that there are shared behavioral patterns in  
308 using tobacco and cannabis, the psychological principles and behavioral change techniques used  
309 in tobacco cessation programs could be adapted to assist people who co-use both substances.<sup>64</sup>

310

311

## 312 **CONCLUSIONS**

313 More than a quarter of callers to the California tobacco quitline were people who co-use  
314 cigarettes and cannabis, and nearly half of them intended to quit using cannabis soon. People  
315 who co-use quit cigarette smoking at a lower rate than those who did not use cannabis. Given  
316 that cannabis use is on the rise even as tobacco use declines, the proportion of people who co-use  
317 among those using tobacco seeking help in places like quitlines is likely to increase. The state  
318 quitlines, which collectively serve a very large number of people who use tobacco in the U.S.  
319 every year,<sup>65</sup> represent a unique place to understand the co-use condition and to develop  
320 corresponding programs to help those who co-use stop using both substances.

## 321 **ACKNOWLEDGEMENTS**

322 The study was approved by the Human Research Protections Program of the University of  
323 California, San Diego (#171562). This research was supported by the California Department of  
324 Public Health (contract numbers CDPH-19-10009 and CDPH-22-10081) and First 5 California  
325 (CFF-7401 and CFF-7602). The funding agencies had no role in study design, data collection,  
326 analysis, interpretation, writing the report, or submission for publication. No conflicts of interest  
327 were reported by the authors of this paper. No financial disclosures were reported by the authors.

328

## 329 **REFERENCES**

330

- 331 1. Cornelius ME. Tobacco Product Use Among Adults – United States, 2021. *MMWR Morb*  
332 *Mortal Wkly Rep.* 2023;72. doi:10.15585/mmwr.mm7218a1
- 333 2. Jamal A. Current Cigarette Smoking Among Adults — United States, 2005–2015. *MMWR*  
334 *Morb Mortal Wkly Rep.* 2016;65. doi:10.15585/mmwr.mm6544a2
- 335 3. 2021 NSDUH Detailed Tables | CBHSQ Data. Accessed October 11, 2023.  
336 <https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables>
- 337 4. Results from the 2015 National Survey on Drug Use and Health: Detailed Tables | CBHSQ  
338 Data. Accessed November 5, 2023. [https://www.samhsa.gov/data/report/results-2015-](https://www.samhsa.gov/data/report/results-2015-national-survey-drug-use-and-h)  
339 [national-survey-drug-use-and-h](https://www.samhsa.gov/data/report/results-2015-national-survey-drug-use-and-h)
- 340 5. Akbar SA, Tomko RL, Salazar CA, Squeglia LM, McClure EA. Tobacco and cannabis co-use  
341 and interrelatedness among adults. *Addict Behav.* 2019;90:354-361.  
342 doi:10.1016/j.addbeh.2018.11.036
- 343 6. Hindocha C, McClure EA. Unknown population-level harms of cannabis and tobacco co-use:  
344 If you don't measure it, you can't manage it. *Addict.* 2021;116(7):1622-1630.  
345 doi:10.1111/add.15290
- 346 7. Tucker JS, Rodriguez A, Dunbar MS, et al. Cannabis and tobacco use and co-use: Trajectories  
347 and correlates from early adolescence to emerging adulthood. *Drug Alcohol Depend.*  
348 2019;204:107499. doi:10.1016/j.drugalcdep.2019.06.004



- 349 8. Schauer GL, Berg CJ, Kegler MC, Donovan DM, Windle M. Assessing the overlap between  
350 tobacco and marijuana: Trends in patterns of co-use of tobacco and marijuana in adults from  
351 2003-2012. *Addict Behav.* 2015;49:26-32. doi:10.1016/j.addbeh.2015.05.012
- 352 9. Goodwin RD, Pacek LR, Copeland J, et al. Trends in Daily Cannabis Use Among Cigarette  
353 Smokers: United States, 2002–2014. *Am J Public Health.* 2018;108(1):137-142. doi:10.2105/  
354 AJP.2017.304050
- 355 10. Ream GL, Benoit E, Johnson BD, Dunlap E. Smoking tobacco along with marijuana  
356 increases symptoms of cannabis dependence. *Drug Alcohol Depend.* 2008;95(3):199-208.  
357 doi:10.1016/j.drugalcdep.2008.01.011
- 358 11. Reboussin BA, Wagoner KG, Ross JC, Suerken CK, Sutfin EL. Tobacco and marijuana co-  
359 use in a cohort of young adults: Patterns, correlates and reasons for co-use. *Drug Alcohol*  
360 *Depend.* 2021;227:109000. doi:10.1016/j.drugalcdep.2021.109000
- 361 12. Smith DM, Miller C, O'Connor RJ, et al. Modes of delivery in concurrent nicotine and  
362 cannabis use (“co-use”) among youth: findings from the International Tobacco Control (ITC)  
363 Survey. *Subst Abuse.* 2021;42(3):339-347. doi:10.1080/08897077.2019.1709603
- 364 13. Pacek LR, Copeland J, Dierker L, Cunningham CO, Martins SS, Goodwin RD. Among  
365 whom is cigarette smoking declining in the United States? The impact of cannabis use status,  
366 2002–2015. *Drug Alcohol Depend.* 2018;191:355-360. doi:10.1016/j.drugalcdep.2018.01.040
- 367 14. Weinberger AH, Pacek LR, Wall MM, Gbedemah M, Lee J, Goodwin RD. Cigarette  
368 smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders,  
369 2002-2016. *Tob Control.* 2020;29(1):74-80. doi:10.1136/tobaccocontrol-2018-054590
- 370 15. Strong DR, Myers MG, Pulvers K, Noble M, Brikmanis K, Doran N. Marijuana use among  
371 US tobacco users: Findings from wave 1 of the population assessment of tobacco health  
372 (PATH) study. *Drug Alcohol Depend.* 2018;186:16-22. doi:10.1016/j.drugalcdep.2017.12.044
- 373 16. California Health Interview Survey (CHIS) 2022 Making an Impact. UCLA Center for  
374 Health Policy Research. Accessed November 8, 2023. <https://healthpolicy.ucla.edu/>
- 375 17. Li S, Wang, J, Zhu SH (2024). Modes of Cannabis Consumption: Results from a California  
376 Statewide Survey. To be presented at The College on Problems of Drug Dependence 86th  
377 Annual Scientific Meeting; June 15-19, 2024; Quebec, Canada.
- 378 18. CDC. Smoking and Tobacco Use. Smoking Cessation: A Report of the Surgeon General.  
379 Atlanta, GA: US Department of Health and Human Services, CDC; 2020.  
380 <https://www.cdc.gov/tobacco/sgr/2020-smoking-cessation/index.html>.
- 381 19. National Center for Chronic Disease Prevention and Health Promotion (US) Office on  
382 Smoking and Health. *The Health Consequences of Smoking—50 Years of Progress: A Report*

- 383 *of the Surgeon General*. Centers for Disease Control and Prevention (US); 2014. Accessed  
384 November 5, 2023. <http://www.ncbi.nlm.nih.gov/books/NBK179276/>
- 385 20. Holdman R. Evidence of Health Effects Associated with Marijuana Use: A Comprehensive  
386 Public Health Review. In: *Cannabinoids - Recent Perspectives and Applications in Human*  
387 *Health*. IntechOpen; 2022. doi:10.5772/intechopen.106250
- 388 21. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana  
389 Use. *N Engl J Med*. 2014;370(23):2219-2227. doi:10.1056/NEJMra1402309
- 390 22. Solmi M, De Toffol M, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella  
391 review of meta-analyses of randomised controlled trials and observational studies. *BMJ*.  
392 2023;382:e072348. doi:10.1136/bmj-2022-072348
- 393 23. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and  
394 tobacco: a review. *Addict Abingdon Engl*. 2012;107(7):1221-1233. doi:10.1111/j.1360-  
395 0443.2012.03837.x
- 396 24. Meier E, Vandrey R, Rubin N, et al. Cigarette Smokers Versus Cousers of Cannabis and  
397 Cigarettes: Exposure to Toxicants. *Nicotine Tob Res*. 2020;22(8):1383-1389. doi:10.1093/ntr/  
398 ntz199
- 399 25. Rooke SE, Norberg MM, Copeland J, Swift W. Health outcomes associated with long-term  
400 regular cannabis and tobacco smoking. *Addict Behav*. 2013;38(6):2207-2213.  
401 doi:10.1016/j.addbeh.2013.01.013
- 402 26. Tucker JS, Pedersen ER, Seelam R, Dunbar MS, Shih RA, D'Amico EJ. Types of cannabis  
403 and tobacco/nicotine co-use and associated outcomes in young adulthood. *Psychol Addict*  
404 *Behav*. 2019;33(4):401-411. doi:10.1037/adb0000464
- 405 27. McClure EA, Rabin RA, Lee DC, Hindocha C. Treatment Implications Associated with  
406 Cannabis and Tobacco Co-Use. *Curr Addict Rep*. 2020;7(4):533-544. doi:10.1007/s40429-  
407 020-00334-8
- 408 28. Walsh H, McNeill A, Purssell E, Duaso M. A systematic review and Bayesian meta-analysis  
409 of interventions which target or assess co-use of tobacco and cannabis in single- or multi-  
410 substance interventions. *Addict*. 2020;115(10):1800-1814. doi:10.1111/add.14993
- 411 29. Peters EN, Budney AJ, Carroll KM. Clinical Correlates of Co-Occurring Cannabis and  
412 Tobacco Use: A Systematic Review. *Addict*. 2012;107(8):1404-1417. doi:10.1111/j.1360-  
413 0443.2012.03843.x
- 414 30. Ford DE, Vu HT, Anthony JC. Marijuana use and cessation of tobacco smoking in adults  
415 from a community sample. *Drug Alcohol Depend*. 2002;67(3):243-248. doi:10.1016/S0376-  
416 8716(02)00066-2

- 417 31. Goodwin RD, Shevorykin A, Carl E, et al. Daily Cannabis Use Is a Barrier to Tobacco  
418 Cessation Among Tobacco Quitline Callers at 7-Month Follow-up. *Nicotine Tob Res.*  
419 2022;24(10):1684-1688. doi:10.1093/ntr/ntac096
- 420 32. Rogers AH, Shepherd JM, Buckner JD, et al. Current cannabis use and smoking cessation  
421 among treatment seeking combustible smokers. *Drug Alcohol Depend.* 2020;209:107928.  
422 doi:10.1016/j.drugalcdep.2020.107928
- 423 33. Vogel EA, Rubinstein ML, Prochaska JJ, Ramo DE. Associations between Marijuana Use  
424 and Tobacco Cessation Outcomes in Young Adults. *J Subst Abuse Treat.* 2018;94:69-73.  
425 doi:10.1016/j.jsat.2018.08.010
- 426 34. Weinberger AH, Delnevo CD, Wyka K, et al. Cannabis Use Is Associated With Increased  
427 Risk of Cigarette Smoking Initiation, Persistence, and Relapse Among Adults in the United  
428 States. *Nicotine Tob Res.* 2020;22(8):1404-1408. doi:10.1093/ntr/ntz085
- 429 35. McClure JB, Lapham G. Tobacco quitline engagement and outcomes among primary care  
430 patients reporting use of tobacco or dual tobacco and cannabis: An observational study. *Subst*  
431 *Abuse.* 2021;42(4):417-422. doi:10.1080/08897077.2020.1846665
- 432 36. Rabin RA, Ashare RL, Schnoll RA, et al. Does cannabis use moderate smoking cessation  
433 outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial. *Am*  
434 *J Addict.* 2016;25(4):291-296. doi:10.1111/ajad.12382
- 435 37. Westmaas JL, Strollo SE, Newton CC, et al. Association between Smoking Cannabis and  
436 Quitting Cigarettes in a Large American Cancer Society Cohort. *Cancer Epidemiol Biomark*  
437 *Prev.* 2021;30(10):1956-1964. doi:10.1158/1055-9965.EPI-20-1810
- 438 38. Matkin W, Ordóñez-Mena JM, Hartmann-Boyce J. Telephone counselling for smoking  
439 cessation. *Cochrane Database Syst Rev.* 2019;(5). doi:10.1002/14651858.CD002850.pub4
- 440 39. Tedeschi GJ, Cummins SE, Anderson CM, Anthenelli RM, Zhuang YL, Zhu SH. Smokers  
441 with Self-Reported Mental Health Conditions: A Case for Screening in the Context of  
442 Tobacco Cessation Services. *PloS One.* 2016;11(7):e0159127.  
443 doi:10.1371/journal.pone.0159127
- 444 40. Morris CD, Lukowski AV, Vargas-Belcher RA, Ylioja TE, Nash CM, Bailey LA. Quitline  
445 Programs Tailored for Mental Health: Initial Outcomes and Feasibility. *Am J Prev Med.*  
446 2021;60(3 Suppl 2):S163-S171. doi:10.1016/j.amepre.2020.02.025
- 447 41. Carpenter KM. Marijuana Use and Adherence to Smoking Cessation Treatment Among  
448 Callers to Tobacco Quitlines. *Prev Chronic Dis.* 2020;17. doi:10.5888/pcd17.200110
- 449 42. Aletraris L, Graves BD, Ndung'u JJ. Assessing the Impact of Recreational Cannabis  
450 Legalization on Cannabis Use Disorder and Admissions to Treatment in the United States.  
451 *Curr Addict Rep.* 2023;10(2):198-209. doi:10.1007/s40429-023-00470-x

- 452 43. Zhu SH, Anderson CM, Johnson CE, Tedeschi G, Roeseler A. A centralised telephone  
453 service for tobacco cessation: the California experience. *Tob Control*. 2000;9 Suppl 2(Suppl  
454 2):II48-55. doi:10.1136/tc.9.suppl\_2.ii48
- 455 44. Zhu SH, Tedeschi GJ, Anderson CM, Pierce JP. Telephone Counseling for Smoking  
456 Cessation: What's in a Call? *J Couns Dev*. 1996;75(2):93-102. doi:10.1002/j.1556-  
457 6676.1996.tb02319.x
- 458 45. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a  
459 telephone quitline for smokers. *N Engl J Med*. 2002;347(14):1087-1093.  
460 doi:10.1056/NEJMsa020660
- 461 46. SAS [computer program]. Version 9.4. Cary, NC: SAS Institute Inc; 2014.
- 462 47. Kick It California - Reports. Kick It California. Accessed November 5, 2023.  
463 <https://kickitca.org/reports>, <https://kickitca.org/reports>
- 464 48. Jeffers AM, Glantz S, Byers A, Keyhani S. Sociodemographic Characteristics Associated  
465 With and Prevalence and Frequency of Cannabis Use Among Adults in the US. *JAMA Netw*  
466 *Open*. 2021;4(11):e2136571. doi:10.1001/jamanetworkopen.2021.36571
- 467 49. Schauer GL, Berg CJ, Kegler MC, Donovan DM, Windle M. Differences in Tobacco Product  
468 Use Among Past Month Adult Marijuana Users and Nonusers: Findings From the 2003-2012  
469 National Survey on Drug Use and Health. *Nicotine Tob Res*. 2016;18(3):281-288.  
470 doi:10.1093/ntr/ntv093
- 471 50. Weinberger AH, Platt J, Copeland J, Goodwin RD. Is Cannabis Use Associated With  
472 Increased Risk of Cigarette Smoking Initiation, Persistence, and Relapse? Longitudinal Data  
473 From a Representative Sample of US Adults. *J Clin Psychiatry*. 2018;79(2):17m11522.  
474 doi:10.4088/jcp.17m11522
- 475 51. Subramaniam P, McGlade E, Yurgelun-Todd D. Comorbid Cannabis and Tobacco Use in  
476 Adolescents and Adults. *Curr Addict Rep*. 2016;3(2):182-188. doi:10.1007/s40429-016-0101-  
477 3
- 478 52. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. *Annu Rev Psychol*.  
479 2013;64(1):21-47. doi:10.1146/annurev-psych-113011-143739
- 480 53. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in  
481 drug addiction. *Trends Neurosci*. 2006;29(4):225-232. doi:10.1016/j.tins.2006.01.008
- 482 54. Scherma M, Fadda P, Le Foll B, et al. The endocannabinoid system: a new molecular target  
483 for the treatment of tobacco addiction. *CNS Neurol Disord Drug Targets*. 2008;7(5):468-481.
- 484 55. Lemyre A, Poliakova N, Bélanger RE. The Relationship Between Tobacco and Cannabis  
485 Use: A Review. *Subst Use Misuse*. 2019;54(1):130-145. doi:10.1080/10826084.2018.1512623

- 486 56. Rubinstein ML, Rait MA, Prochaska JJ. Frequent marijuana use is associated with greater  
487 nicotine addiction in adolescent smokers. *Drug Alcohol Depend.* 2014;141:159-162.  
488 doi:10.1016/j.drugalcdep.2014.05.015
- 489 57. Sehl H, Terrett G, Greenwood LM, et al. Patterns of brain function associated with cannabis  
490 cue-reactivity in regular cannabis users: A systematic review of fMRI studies.  
491 *Psychopharmacology (Berl)*. 2021;238(10):2709-2728. doi:10.1007/s00213-021-05973-x
- 492 58. Rabin RA, McClure EA, George TP. Tobacco Use among Individuals with Cannabis Use:  
493 Insights into Co-use and Why It Matters for People with Psychosis. In: Castle D, D'Souza  
494 DC, Murray SR, eds. *Marijuana and Madness*. 3rd ed. Cambridge University Press;  
495 2023:310-320. doi:10.1017/9781108943246.030
- 496 59. Shadel WG, Cervone D. The Role of the Self in Smoking Initiation and Smoking Cessation:  
497 A Review and Blueprint for Research at the Intersection of Social-Cognition and Health. *Self*  
498 *Identity*. 2011;10(3):386-395. doi:10.1080/15298868.2011.557922
- 499 60. Falomir-Pichastor JM, Blondé J, Desrichard O, Felder M, Riedo G, Folly L. Tobacco  
500 dependence and smoking cessation: The mediating role of smoker and ex-smoker self-  
501 concepts. *Addict Behav.* 2020;102:106200. doi:10.1016/j.addbeh.2019.106200
- 502 61. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in  
503 treatment for or recovery from substance use disorders. *Cochrane Database Syst Rev.* 2016;  
504 (11). doi:10.1002/14651858.CD010274.pub2
- 505 62. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with  
506 individuals in substance abuse treatment or recovery. *J Consult Clin Psychol.*  
507 2004;72(6):1144-1156. doi:10.1037/0022-006X.72.6.1144
- 508 63. McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment  
509 on substance use outcomes: An updated and narrative review. *Addict Behav.* 2017;65:161-  
510 170. doi:10.1016/j.addbeh.2016.10.012
- 511 64. Becker J, Hungerbuehler I, Berg O, et al. Development of an integrative cessation program  
512 for co-smokers of cigarettes and cannabis: demand analysis, program description, and  
513 acceptability. *Subst Abuse Treat Prev Policy.* 2013;8:33. doi:10.1186/1747-597X-8-33
- 514 65. North American Quitline Consortium. 2022. NAQC FY22 Annual Survey: A National  
515 Progress Update. K. Mason, editor. Available at [www.naquitline.org/page/2022survey](http://www.naquitline.org/page/2022survey).

516 **Table 1.** Baseline Characteristics of Quitline Clients Seeking Help to Quit Smoking by Cannabis Use  
 517 Status, 2020-2023

<b>Characteristic</b>	<b>Cannabis Users</b>	<b>Non-Users</b>
	<b>N=12,283</b>	<b>N=32,868</b>
	<b>% (95% CI)</b>	<b>% (95% CI)</b>
<b>Gender</b>		
Male	48.4 (47.6-49.3)	44.4 (43.8-44.9)
Female	49.2 (48.4-50.1)	54.0 (53.4-54.5)
Other Gender/Decline	2.3 (2.0-2.6)	1.7 (1.5-1.8)
<b>Age Group (years)</b>		
<25	3.4 (3.1-3.7)	1.6 (1.5-1.8)
25-44	32.7 (31.9-33.5)	26.1 (25.7-26.6)
45-64	47.7 (46.9-48.6)	49.7 (49.1-50.2)
≥ 65	16.1 (15.5-16.8)	22.6 (22.1-23.0)
<b>Race/Ethnicity</b>		
White	52.1 (51.2-53.0)	44.7 (44.2-45.3)
Black	18.4 (17.7-19.1)	14.6 (14.2-14.9)
Hispanic	13.6 (13.0-14.2)	26.3 (25.8-26.8)
Asian American/Pacific Islander	2.5 (2.2-2.8)	3.8 (3.6-4.0)
American Indian/Alaska Native	1.7 (1.5-2.0)	1.2 (1.1-1.3)
Other	2.7 (2.4-3.0)	3.0 (2.8-3.2)
Multiple Race	9.0 (8.4-9.5)	6.3 (6.1-6.6)
<b>Education</b>		
High School and Lower	44.8 (43.9-45.7)	49.4 (48.8-49.9)
Some College	43.4 (42.5-44.3)	37.5 (36.9-38.0)
College degree and above	11.8 (11.2-12.4)	13.1 (12.8-13.5)
<b>Any Mental Health Condition</b>		
No	38.3 (37.4-39.1)	47.9 (47.4-48.5)
Yes	61.7 (60.9-62.6)	52.1 (51.5-52.6)
<b>Cigarettes per Day at Baseline</b>		
<15	53.9 (53.0-54.8)	54.2 (53.7-54.7)
≥ 15	46.1 (45.2-47.0)	45.8 (45.3-46.3)
<b>Currently Vaping Nicotine</b>		
No	86.9 (86.3-87.5)	91.1 (90.8-91.4)
Yes	13.1 (12.5-13.7)	8.9 (8.6-9.2)

518

519

520

521

522

523

524 **Table 2.** Counseling and Quit Aid Use Rates among Quitline Clients by Cannabis Use Status

Use of Cessation Services	Cannabis Users	Non-Users
	N=964	N=2,581
	% (95% CI)	% (95% CI)
Received Counseling	72.0 (69.2-74.8)	74.5 (72.9-76.2)
Used Any Quit Aids	64.1 (61.1-67.1)	64.9 (63.0-66.7)

525

526

527

528 **Table 3.** 30-Day Abstinence Rate at 7-Month Evaluation, 2020-2023 (N= 3,545)  
 529

<b>Effect</b>	<b>Quit Rate % (95% CI)</b>	<b>Multiple Logistic Regression Odds Ratio (95% CI)</b>
<b>Cannabis Use</b>		
No	28.9 (27.2-30.7)	Ref
Yes	23.2 (20.6-25.9)	0.73 (0.61-0.88)
<b>Gender</b>		
Male	29.0 (26.9-31.2)	Ref
Female	25.7 (23.7-27.7)	0.88 (0.75-1.03)
Other Gender	35.0 (20.2-49.8)	1.15 (0.52-2.58)
<b>Age Group (years)</b>		
<25	39.4 (30.3-48.6)	1.73 (1.10-2.72)
25-44	32.3 (29.7-35.0)	1.37 (1.09-1.73)
40-64	24.0 (21.9-26.1)	0.95 (0.76-1.18)
≥ 65	24.7 (21.3-28.0)	Ref
<b>Race/Ethnicity</b>		
White	27.3 (25.1-29.6)	Ref
Black	21.8 (18.2-25.4)	0.69 (0.53-0.88)
Hispanic	29.5 (26.5-32.4)	0.94 (0.77-1.15)
Asian American/Pacific Islander	37.0 (28.9-45.0)	1.06 (0.72-1.55)
American Indian/Alaska Native/Other	29.1 (21.9-36.4)	1.02 (0.70-1.48)
Multiple Race	25.8 (20.5-31.0)	0.81 (0.60-1.11)
<b>Education</b>		
High School and Lower	26.3 (24.1-28.4)	Ref
Some College	27.7 (25.3-30.0)	1.08 (0.91-1.29)
College Degree and above	31.0 (26.9-35.0)	1.17 (0.93-1.48)
<b>Any Mental Health Condition</b>		
No	30.6 (28.3-32.9)	Ref
Yes	25.0 (23.1-26.9)	0.74 (0.63-0.87)
<b>Cigarettes per Day at Baseline</b>		
<15	31.4 (29.3-33.4)	Ref
≥ 15	22.2 (20.1-24.2)	0.60 (0.51-0.71)
<b>Currently Vaping Nicotine</b>		
No	26.0 (24.4-27.6)	Ref
Yes	32.3 (29.0-35.6)	1.28 (1.06-1.54)
<b>Receiving Counseling</b>		
No	23.9 (21.1-26.6)	Ref
Yes	29.4 (27.7-31.1)	1.26 (1.05-1.51)
<b>Used Any Quit Aids</b>		
No	23.7 (21.4-26.0)	Ref
Yes	30.3 (28.5-32.2)	1.46 (1.24-1.72)

530

531

532